Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talquetamab - Genmab/Janssen Research & Development

Next Previous
X
Search
Drug Profile

Talquetamab - Genmab/Janssen Research & Development

Alternative Names: GPRC5D/CD3-duobody-antibody-JNJ-64407564; JNJ 64407564; JNJ-7564; TALVEY

Latest Information Update: 02 Sep 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab; Janssen Research & Development
  • Developer Janssen Research & Development
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Multiple myeloma
  • Phase II Smoldering multiple myeloma

Most Recent Events

  • 23 Aug 2024 Phase-II clinical trials in Multiple myeloma (Second-line therapy or greater) in United Kingdom (Northern Ireland), United Kingdom, Netherlands, Brazil (SC) (ISRCTN72589181)
  • 19 Aug 2024 Janssen Research & Development plans a phase II MonumenTAL-8 trial for Multiple Myeloma (Combination therapy, Second-line therapy or greater) in September 2024 (SC) (NCT06550895)
  • 18 Jul 2024 Janssen Research & Development plans a phase II trial for Multiple meyloma (Second-line therapy or greater) (SC) in Brazil, England, Netherlands, South Korea, Spain, United Kingdom, United Kingdom (Northern Ireland), USA in August 2024 (NCT06500884)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top